UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

A Randomized Phase II Study of LY2510924 and Carboplatin/Etoposide versus Carboplatin/Etoposide in Extensive‐Disease Small Cell Lung Cancer

Lung cancer (Amsterdam, Netherlands), 2017-03, Vol.105, p.7-13

2017

Volltextzugriff (PDF)

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Journal of clinical oncology, 2004-11, Vol.22 (22), p.4456-4462

2004

Volltextzugriff (PDF)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001095

2020

Volltextzugriff (PDF)

Features of genetic algorithm for plain text encryption

International journal of electrical and computer engineering (Malacca, Malacca), 2021-02, Vol.11 (1), p.434

2021

Volltextzugriff (PDF)

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5597-5604

2005

Volltextzugriff (PDF)

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1498-1504

2003

Volltextzugriff (PDF)

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2017-11, Vol.390 (10109), p.2266-2277

2017

Volltextzugriff (PDF)

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

The lancet oncology, 2020-01, Vol.21 (1), p.105-120

2020

Volltextzugriff (PDF)

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3156-TPS3156

2023

Volltextzugriff (PDF)

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8604-TPS8604

2023

Volltextzugriff (PDF)

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Targeted oncology, 2017-08, Vol.12 (4), p.463-474

2017

Volltextzugriff (PDF)

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2021-05, Vol.21 (5), p.309-317.e3

2021

Volltextzugriff (PDF)

A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4542-4542

2018

Volltextzugriff (PDF)

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

Leukemia & lymphoma, 2016-01, Vol.57 (1), p.216-218

2016

Volltextzugriff (PDF)

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.353-353

2019

Volltextzugriff (PDF)

Abstract CT058: Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT058-CT058

2016

Volltextzugriff (PDF)

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT124-CT124

2022

Volltextzugriff (PDF)

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4526-4526

2018

Volltextzugriff (PDF)

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

Targeted oncology, 2016-10, Vol.11 (5), p.643-653

2016

Volltextzugriff (PDF)

Open‐label, single‐arm, phase II study of enzastaurin in patients with follicular lymphoma

British journal of haematology, 2014-07, Vol.166 (1), p.91-97

2014

Volltextzugriff (PDF)

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4547-4547

2015

Volltextzugriff (PDF)

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7567-7567

2015

Volltextzugriff (PDF)

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.295-295

2015

Volltextzugriff (PDF)

Abstract 5303: Correlative results from PRELUDE, a phase III study of enzastaurin (ENZA) vs placebo (PBO) in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) following a response to R-CHOP therapy

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5303-5303

2015

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(89)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Life Sciences & Biomedicine
(36)
Science & Technology
(36)
Female
(30)
Oncology
(30)
Male
(29)
Middle Aged
(26)
Aged
(24)
Adult
(20)
Treatment Outcome
(18)
Melanoma - Drug Therapy
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Aged, 80 And Over
(13)
Antineoplastic Agents - Therapeutic Use
(11)
Immunotherapy
(11)
Tumors
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Ipilimumab
(10)
Skin Neoplasms - Drug Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized Phase II Study of LY2510924 and Carboplatin/Etoposide versus Carboplatin/Etoposide in Extensive‐Disease Small Cell Lung Cancer

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Features of genetic algorithm for plain text encryption

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC)

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts)

Abstract CT058: Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

Open‐label, single‐arm, phase II study of enzastaurin in patients with follicular lymphoma

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma

Abstract 5303: Correlative results from PRELUDE, a phase III study of enzastaurin (ENZA) vs placebo (PBO) in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) following a response to R-CHOP therapy

Suchergebnisse filtern